Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer Delves Deeper In Generics Partnership With Strides Arcolab

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer's supply agreement with India-based Strides Arcolab now covers 45 products with a more expansive global marketing reach.

You may also be interested in...

Pfizer, Strides Arcolab Join Forces To Manufacture And Market Oncology Injectables In U.S.

MUMBAI - After partnering with Aurobindo Pharma and Claris to source more than 100 oral and injectable generic drugs last year, Pfizer continues its shopping spree in India as it sealed yet another sourcing deal, this time with Bangalore-based Strides Arcolab

Pfizer Goes Big On Generic Injectables With Acquisition Of 15 Products From India’s Claris

AHMEDABAD, India - Two months after Pfizer signed a comprehensive in-licensing agreement for more than 50 oral and injectable products with Aurobindo Pharma, the U.S. company has entered into another deal, with India's Claris Lifesciences, to commercialize 15 products covering a broad range of therapeutic areas including anti-infectives and pain drugs

Pfizer On The Prowl For Generics

Only weeks after announcing its Wyeth acquisition, Pfizer is stepping up its profile in the generics world, looking for branded and commodity opportunities.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts